Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric bosutinib study in Philadelphia chromosome-positive chronic myeloid leukemia
NL-OMON28987Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bosutinib in chronic myelogenous leukemia (CML) (2 arms), sponsored by Erasmus MC. Primary endpoints: Incidence and severity of dose-limiting toxicities, Bosutinib pharmacokinetic parameters and 2 more. Started Feb 2016; status: recruiting.
02
Drugs
bosutinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on NL-OMON28987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28987.